146 related articles for article (PubMed ID: 16330376)
21. Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity.
Jansen CA; Piriou E; De Cuyper IM; van Dort K; Lange JM; Miedema F; van Baarle D
Antivir Ther; 2006; 11(1):105-16. PubMed ID: 16518966
[TBL] [Abstract][Full Text] [Related]
22. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
[TBL] [Abstract][Full Text] [Related]
23. HIV/AIDS pathogenesis and treatment options focusing on the viral entry inhibitors.
Jones R; Gazzard B
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):303-12. PubMed ID: 16597210
[TBL] [Abstract][Full Text] [Related]
24. Vaccine and immunotherapeutic interventions.
Pantaleo G; Lévy Y
Curr Opin HIV AIDS; 2013 May; 8(3):236-42. PubMed ID: 23478912
[TBL] [Abstract][Full Text] [Related]
25. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
Pippi F
Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
[TBL] [Abstract][Full Text] [Related]
26. [Long term survival after Rhodococcus equi pneumonia in a patient with human immunodeficiency virus infection in the era of highly active antiretroviral therapy: case report and review].
Vladusić I; Krajinović V; Begovac J
Acta Med Croatica; 2006 Jun; 60(3):259-63. PubMed ID: 16933840
[TBL] [Abstract][Full Text] [Related]
27. [HIV eradication--facts and fiction].
Jaeger H; Wolf E
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():72-3. PubMed ID: 19024923
[No Abstract] [Full Text] [Related]
28. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
[TBL] [Abstract][Full Text] [Related]
29. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
[TBL] [Abstract][Full Text] [Related]
30. Treatment interruptions in HIV-infected subjects.
Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
[TBL] [Abstract][Full Text] [Related]
31. Approaches for therapeutic vaccination in HIV infection.
Stebbing J
J HIV Ther; 2005 Sep; 10(3):46-7. PubMed ID: 16385970
[No Abstract] [Full Text] [Related]
32. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
33. AIDS vaccine: efficacy, safety and ethics.
Veljkovic V; Veljkovic N; Glisic S; Ho MW
Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
[TBL] [Abstract][Full Text] [Related]
34. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
35. [Cutaneous drug reactions in HIV-infected patients in the HAART era].
Blanes M; Belinchón I; Portilla J
Actas Dermosifiliogr; 2009 May; 100(4):253-65. PubMed ID: 19463228
[TBL] [Abstract][Full Text] [Related]
36. Progress towards an AIDS mucosal vaccine: an overview.
Yuki Y; Nochi T; Kiyono H
Tuberculosis (Edinb); 2007 Aug; 87 Suppl 1():S35-44. PubMed ID: 17652028
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
[TBL] [Abstract][Full Text] [Related]
38. [HIV vaccination].
Jablonowski H
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():68-9. PubMed ID: 19031568
[No Abstract] [Full Text] [Related]
39. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
Martinez-Picado J; Martínez MA
Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
[TBL] [Abstract][Full Text] [Related]
40. An overview of the human immunodeficiency virus featuring laboratory testing for drug resistance.
Scosyrev E
Clin Lab Sci; 2006; 19(4):231-45; quiz 246-9. PubMed ID: 17181129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
